Vitura Health (ASX:VIT) - Aandelenkoers, Nieuws & Analyse

VIT Overzicht aandelen

Vitura Health Limited houdt zich bezig met de verkoop en distributie van medicinale cannabisproducten in Australië. Meer informatie

VIT fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 33.8% onder onze schatting van de reële waarde

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( A$54M )

Winstmarges (2.8%) zijn lager dan vorig jaar (11.8%)

Vitura Health Limited Concurrenten

ECS Botanics Holdings

ASX:ECS

AU$23.2m

Vita Life Sciences

ASX:VLS

AU$118.3m

Neuren Pharmaceuticals

ASX:NEU

AU$2.0b

EZZ Life Science Holdings

ASX:EZZ

AU$125.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Vitura Health
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.098
52 Week Hoogtepunt	AU$0.32
52 Week Laag	AU$0.068
Bèta	0.016
11 maand verandering	-18.33%
3 maanden verandering	30.67%
1 Jaar Verandering	-68.39%
33 jaar verandering	-52.20%
5 jaar verandering	-57.39%
Verandering sinds IPO	-71.18%

Recent nieuws en updates

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Oct 17

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Oct 13

Recent updates

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Oct 17

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Oct 13

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Sep 07

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Aug 12

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Aug 12

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

Apr 25

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Apr 11

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Feb 27

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Feb 25

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Dec 13

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Nov 21

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Nov 01

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Jul 18

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Sep 12

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Sep 05

Rendement voor aandeelhouders

	VIT	AU Pharmaceuticals	AU Markt
7D	0%	-10.0%	0.4%
1Y	-68.4%	46.9%	16.9%

Rendement versus industrie: VIT presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 46.9 % opleverde.

Rendement versus markt: VIT presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 16.9 % opleverde.

Prijsvolatiliteit

Is VIT's price volatile compared to industry and market?
VIT volatility
VIT Average Weekly Movement	12.2%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.4%

Stabiele aandelenkoers: VIT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van VIT is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2018	n/a	Tom Howitt	vitura.com.au

Vitura Health Limited houdt zich bezig met de verkoop en distributie van medicinale cannabisproducten in Australië. Het is actief in twee segmenten: Verkoop en distributie; en klinieken en diensten. Het bedrijf exploiteert CanView, een online platform dat oplossingen biedt voor het voorschrijven, verstrekken en beheren van medicatie voor alternatieve therapieën; Doctors on Demand, een vooraanstaande leverancier van virtuele gezondheidszorgdiensten op aanvraag; BHC, een distributeur van alternatieve therapieën; CDA Clinics, die medicinale consulten en receptdiensten aanbiedt; en Cannadoc, een medicinale cannabiskliniek die telegezondheidsconsulten aanbiedt.

Vitura Health Limited Samenvatting

Hoe verhouden de winst en inkomsten van Vitura Health zich tot de beurswaarde?
VIT fundamentele statistieken
Marktkapitalisatie	AU$54.13m
Inkomsten(TTM)	AU$3.51m
Inkomsten(TTM)	AU$123.87m

16.1x

Koers/Winstverhouding

0.5x

P/S-verhouding

Is VIT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VIT resultatenrekening (TTM)
Inkomsten	AU$123.87m
Kosten van inkomsten	AU$89.65m
Brutowinst	AU$34.22m
Overige uitgaven	AU$30.71m
Inkomsten	AU$3.51m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.0061
Brutomarge	27.63%
Nettowinstmarge	2.84%
Schuld/Eigen Vermogen Verhouding	13.8%

Hoe presteerde VIT op de lange termijn?

Bekijk historische prestaties en vergelijking

VIT Overzicht aandelen

Beloningen

Risicoanalyse

Vitura Health Limited Concurrenten

ASX:ECS

AU$23.2m

ASX:VLS

AU$118.3m

ASX:NEU

AU$2.0b

ASX:EZZ

AU$125.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Crisci Group and Vitura Health Limited (ASX:VIT) acquired Assets of Releaf Group from Releaf Group Ltd for AUD 6.07 million .

Vitura Health Limited Announces Step Down of Directors

Now 22% undervalued

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Recent updates

Crisci Group and Vitura Health Limited (ASX:VIT) acquired Assets of Releaf Group from Releaf Group Ltd for AUD 6.07 million .

Vitura Health Limited Announces Step Down of Directors

Now 22% undervalued

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

Full year 2024 earnings released: EPS: AU$0.006 (vs AU$0.025 in FY 2023)

Vitura Health Limited Resolves Not to Pay A Dividend in Respect of the Year Ended 30 June 2024

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Less than half of directors are independent

Board Member recently sold AU$1.1m worth of stock

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

New major risk - Share price stability

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Now 39% undervalued after recent price drop

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Vitura Health Limited Receives Shareholder Requisition from Elizabeth Sarah Jansen

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Vitura Health Limited (ASX:VIT) completed the acquisition of acquire an unknown stake in Doctors on Demand from Yeates Ventures Pty Ltd and Kirsty Garrett.

New minor risk - Shareholder dilution

Vitura Health Limited, Annual General Meeting, Nov 28, 2023

Upcoming dividend of AU$0.01 per share at 2.7% yield

Vitura Health Limited Announces Dividend for the Year Ended 30 June 2023, Payable on or Around, 28 September 2023

New major risk - Earnings quality

New minor risk - Financial data availability

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Insider recently sold AU$2.3m worth of stock

New minor risk - Share price stability

Chief Commercial Officer recently sold AU$5.9m worth of stock

High number of new and inexperienced directors

Cronos Australia Limited Announces Changes to Clinical Operations

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Ceases of Benjamin D.N. Jansen as Chief Medical Officer

Cronos Australia Limited Provides Update on Canview 2.0 Platform

Cronos Australia Limited, Annual General Meeting, Nov 29, 2022

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Cronos Australia Limited Appoints Jenelle Frewen and Simone Scovell as Independent Non-Executive Director

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Cronos Australia Limited Announces Dividend for the Year Ended 30 June 2022, Dividend Payment Date Is 11 October 2022

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

Cronos Australia Announces Resignation of Shane Tanner, Chairman and Director

Cronos Australia Limited Announces Resignation of Kurt Thomas Schmidt as Director

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cronos Australia Limited (ASX:CAU) completed the acquisition of Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited (ASX:CAU) entered into Merger implementation agreement to acquire Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited Announces Launch of Additional Products in Key Asian Markets